Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
Rose Essential Oils Market Research is an intelligence report with meticulous efforts to investigate the correct and valuable information. The data that has...